Charles River Laboratories (CRL)

Currency in USD
168.05
-2.83(-1.66%)
Closed·
168.050.00(0.00%)
·
CRL Scorecard
Full Analysis
Management has been aggressively buying back shares
CRL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
165.74171.50
52 wk Range
91.86222.10
Key Statistics
Prev. Close
170.88
Open
168.91
Day's Range
165.74-171.5
52 wk Range
91.86-222.1
Volume
900.95K
Average Volume (3m)
984K
1-Year Change
-20.09%
Book Value / Share
69.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
186.87
Upside
+11.20%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Charles River Laboratories Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization. In additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories Earnings Call Summary for Q3/2025

  • Charles River Labs exceeded Q3 2025 forecasts with $2.43 EPS and $1B revenue, yet stock fell 6.66% amid 0.5% organic revenue decline and 20bps operating margin contraction
  • Company announced $225M cost-saving measures by 2026 while maintaining full-year non-GAAP EPS guidance between $10.10-$10.30 with projected 1.5-2.5% organic revenue decline
  • CEO Jim Foster highlighted the company's 'scientifically differentiated portfolio' positioned to capitalize on biopharmaceutical landscape opportunities
  • Improved biotech funding and decreased cancellation rates signal potential market recovery, though investors remain cautious about growth prospects
  • Management implemented strategic pricing and increased flexibility in response to market demands while pursuing acquisition opportunities for 2026 growth
Last Updated: 05/11/2025, 17:34
Read Full Transcript

Compare CRL to Peers and Sector

Metrics to compare
CRL
Peers
Sector
Relationship
P/E Ratio
−99.1x23.6x−0.6x
PEG Ratio
0.82−0.460.00
Price/Book
2.4x1.9x2.6x
Price / LTM Sales
2.1x2.2x3.3x
Upside (Analyst Target)
10.1%17.7%43.2%
Fair Value Upside
Unlock11.2%7.0%Unlock

Analyst Ratings

9 Buy
8 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 186.87
(+11.20% Upside)

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
2.43 / 2.34
Revenue / Forecast
1.00B / 987.43M
EPS Revisions
Last 90 days

CRL Income Statement

People Also Watch

155.29
GNRC
+0.98%
134.84
ALGN
+0.83%
35.81
VSAT
+0.90%
242.94
LFUS
+0.71%
68.36
HAE
+1.86%

FAQ

What Is the Charles River Laboratories (CRL) Premarket Price Today?

The Charles River Laboratories (CRL) premarket price is 169.00. Premarket price change units: -1.88. Premarket percentage change: -1.10%. Premarket volume: 1,770.00. Current date: 08 Nov 2025. Previous close: 170.88

What Stock Exchange Does Charles River Laboratories Trade On?

Charles River Laboratories is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Charles River Laboratories?

The stock symbol for Charles River Laboratories is "CRL."

What Is the Charles River Laboratories (CRL) Afterhours Price Today? (Afterhours variable test: 168.05) Current Date: 08 Nov 2025

After hours price: 168.05. After hours price change (units): 0.00. Price change percentage: 0.00%

What Is the Charles River Laboratories Market Cap?

As of today, Charles River Laboratories market cap is 8.27B.

What Is Charles River Laboratories's Earnings Per Share (TTM)?

The Charles River Laboratories EPS (TTM) is -1.67.

When Is the Next Charles River Laboratories Earnings Date?

Charles River Laboratories will release its next earnings report on 17 Feb 2026.

From a Technical Analysis Perspective, Is CRL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Charles River Laboratories Stock Split?

Charles River Laboratories has split 0 times.

How Many Employees Does Charles River Laboratories Have?

Charles River Laboratories has 19400 employees.

What is the current trading status of Charles River Laboratories (CRL)?

As of 08 Nov 2025, Charles River Laboratories (CRL) is trading at a price of 168.05, with a previous close of 170.88. The stock has fluctuated within a day range of 165.74 to 171.50, while its 52-week range spans from 91.86 to 222.10.

What Is Charles River Laboratories (CRL) Price Target According to Analysts?

The average 12-month price target for Charles River Laboratories is USD186.86667, with a high estimate of USD211 and a low estimate of USD155. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +11.20% Upside potential.

What Is the CRL Premarket Price?

CRL's last pre-market stock price is 169.00. The pre-market share volume is 1,770.00, and the stock has decreased by -1.88, or -1.10%.

What Is the CRL After Hours Price?

CRL's last after hours stock price is 168.05, the stock has decreased by 0.00, or 0.00%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.